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Drug delivery systems are becoming increasingly sophisticated as pharmaceutical scientists 
acquire a better understanding of the physicochemical and biochemical parameters pertinent 
to their performance. Over the past three decades, orally disintegrating tablets (ODTs) have 
gained considerable attention as a preferred alternative to conventional tablets and capsules 
due to better patient compliance. ODTs are solid dosage forms containing medicinal 
substances which disintegrate rapidly, usually in a matter of seconds, when placed on the 
tongue. Products of ODT technologies entered the market in the 1980s, have grown steadily 
in demand, and their product pipelines are rapidly expanding. New ODT technologies address 
many pharmaceutical and patient needs, ranging from enhanced life-cycle management to 
convenient dosing for paediatric, geriatric, and psychiatric patients with dysphagia. This has 
encouraged both academia and industry to generate new orally disintegrating formulations 
and technological approaches in this field. The aim of this article is to review the development 
of ODTs, challenges in formulation, new ODT technologies and evaluation methodologies, 
suitability of drug candidates, and future prospects.  
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Introduction 
 
For the past one decade, there has been an 
enhanced demand for more patient-friendly 
and compliant dosage forms. As a result, the 
demand for developing new technologies has 
been increasing annually1. Since the 
development cost of a new drug molecule is 
very high, efforts are now being made by 
pharmaceutical companies to focus on the 
development of new drug dosage forms for 
existing drugs with improved safety and 
efficacy together with reduced dosing 
frequency, and the production of more cost-
effective dosage forms. 
 
For most therapeutic agents used to produce 
systemic effects, the oral route still represents 
the preferred way of administration, owing to 
its several advantages and high patient 
compliance compared to many other routes2. 
Tablets and hard gelatin capsules constitute a 
major portion of drug delivery systems that are 
currently available. However, many patient 
groups such as the elderly, children, and 
patients who are mentally retarded, 
uncooperative, nauseated, or on reduced 
liquid-intake/diets have difficulties swallowing 
these dosage forms. Those who are traveling 
or have little access to water are similarly 
affected3-5.  
 
To fulfill these medical needs, pharmaceutical 
technologists have developed a novel oral 
dosage form known as Orally Disintegrating 
Tablets (ODTs) which disintegrate rapidly in 
saliva, usually in a matter of seconds, without 
the need to take it water. Drug dissolution and 
absorption as well as onset of clinical effect 
and drug bioavailability may be significantly 
greater than those observed from 
conventional dosage forms6-8. 
 
Although chewable tablets have been on the 
market for some time, they are not the same 
as the new ODTs. Patients for whom chewing 
is difficult or painful can use these new tablets 
easily. ODTs can be used easily in children 
who have lost their primary teeth but do not 
have full use of their permanent teeth9. 
Recent market studies indicate that more than 
half of the patient population prefers ODTs to 
other dosage forms10 and most consumers 
would ask their doctors for ODTs (70%), 
purchase ODTs (70%), or prefer ODTs to 
regular tablets or liquids (>80%)11. 
 
The US Food and Drug Administration Center 
for Drug Evaluation and Research (CDER) 
defines, in the ‘Orange Book’, an ODT as “a 
solid dosage form containing medicinal 
substances, which disintegrates rapidly, 
usually within a matter of seconds, when 
placed upon the tongue”12. The significance of 
these dosage forms is highlighted by the 
adoption of the term, “Orodispersible Tablet”, 
by the European Pharmacopoeia which 
describes it as a tablet that can be placed in 
oral cavity where it disperses rapidly before 
swallowing13.  
 
ODT products have been developed for 
numerous indications ranging from migraines 
(for which rapid onset of action is important) to 
mental illness (for which patient compliance is 
important for treating chronic indications such 
as depression and schizophrenia)14. 
 
Descriptions of Orally Disintegra-
ting Dosage Forms 
 
ODTs are distinguished from conventional 
sublingual tablets, buccal tablets, and 
lozenges, which require more than a minute to 
dissolve in oral cavity. In the literature, ODTs 
also are called orodisperse, mouth-dissolving, 
quick-dissolve, fast-melt, and freeze-dried 
wafers. 
 
A freeze-dried wafer is a quick-dissolving, 
thin matrix that contains a medicinal agent 
that does not need water for swallowing. This 
fragile dosage form requires unit-dose 
packaging to ensure physical stability. The 
wafer disintegrates instantaneously in the oral 
cavity and releases drug, which dissolves or 
disperses in the saliva. The saliva is 
swallowed and the drug is absorbed across 
the gastrointestinal tract (GIT)15. 
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- An orally disintegrating tablet (ODT) is a 
solid dosage form that contains medicinal 
substances and disintegrates rapidly (within 
seconds) without water when placed on the 
tongue. The drug is released, dissolved, or 
dispersed in the saliva, and then swallowed 
and absorbed across the GIT13. 
 
A quick-dissolving tablet (also known as a 
fast-dissolving, fast-dissolving multiparticulate, 
rapid-dissolving, mouth-dissolving, fast-
melting, or orodispersing tablets) is an oral 
tablet that does not require water for 
swallowing. The tablet dissolves within 60 
seconds when placed in the mouth. The active 
ingredients are absorbed through mucous 
membranes in the mouth and GIT and enter 
the blood stream. A fraction of pregastric drug 
absorption may bypass the digestive system 
and metabolism by the stomach acids and 
enzymes. In general, the tablets are physically 
robust and can be packaged in multidose 
containers16. 
 
Ideal properties of ODTs 
 
The performance of ODTs depends on the 
technology used during their manufacture. 
The necessary property of such tablets is the 
ability to disintegrate rapidly and disperse or 
dissolve in saliva, thereby obviating the need 
for water. Various technologies have been 
developed that enable ODT to perform this 
unique function. An ideal ODT should meet 
the following criteria: 
 
• does not require water for oral 
administration yet disintegrates and 
dissolves in oral cavity within a few 
seconds 
• has sufficient strength to withstand the 
rigors of the manufacturing process and 
post-manufacturing handling 
• allow high drug loading 
• has a pleasant mouth feel 
• is insensitive to environmental 
conditions such as humidity and 
temperature 
• is adaptable and amenable to existing 
processing and packaging machineries 
• is cost-effective. 
 
The Need for Development of ODTS 
 
The need for non-invasive delivery systems 
persists due to patients’ poor acceptance of, 
and compliance with, existing delivery 
regimes, limited market size for drug 
companies and drug uses, coupled with high 






Orally disintegrating dosage forms are 
particularly suitable for patients, who for one 
reason or the other, find it inconvenient to 
swallow traditional tablets and capsules with 
an 8-oz glass of water. These include the 
following: 
 
• Pediatric and geriatric patients who have 
difficulty in swallowing or chewing solid 
dosage forms  
• Patients who are unwilling to take solid 
preparation due to fear of choking  
• Very elderly patients who may not be 
able to swallow a daily dose of 
antidepressant. 
• An eight-year old with allergies who 
desires a more convenient dosage form 
than antihistamine syrup  
• A middle-aged woman undergoing 
radiation therapy for breast cancer may 
be too nauseous to swallow her H2-
blocker  
• A schizophrenic patient in an institutional 
setting who may try to hide a 
conventional tablet under his or her 
tongue to avoid their daily dose of an 
atypical antipsychotic  
• A patient with persistent nausea, who 
may be journey, or has little or no access 




Increased bioavailability and faster onset of 
action are a major claim of these formulations. 
Dispersion in saliva in oral cavity causes pre-
gastric absorption from some formulations in 
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those cases where drug dissolves quickly.  
Buccal, pharyngeal and gastric regions are all 
areas of absorption for many drugs21. Any pre-
gastric absorption avoids first pass 
metabolism and can be a great advantage in 
drugs that undergo a great deal of hepatic 
metabolism. Furthermore, safety profiles may 
be improved for drugs that produce significant 
amounts of toxic metabolites mediated by 
first-pass liver metabolism and gastric 
metabolism, and for drugs that have a 
substantial fraction of absorption in the oral 
cavity and pregastric segments of GIT22. 
 
Manufacturing and marketing factors 
 
Developing new drug delivery technologies 
and utilizing them in product development is 
critical for pharmaceutical industries to 
survive, regardless of their size. As a drug 
nears the end of its patent life, it is common 
for pharmaceutical manufacturers to develop 
a given drug entity in a new and improved 
dosage form. A new dosage form allows a 
manufacturer to extend market exclusivity, 
unique product differentiation, value-added 
product line extension, and extend patent 
protection, while offering its patient population 
a more convenient dosage form. This leads to 
increased revenue, while also targeting 
underserved and under-treated patient 
populations23.  
 
As examples, Eisai Inc. launched Aricept 
ODT, a line extension of donepezil for 
Alzheimer’s disease, in Japan in 2004 and in 
the U.S. in 2005 in response to a generic 
challenge filed in the U.S. by Ranbaxy. 
Merck’s Japanese subsidiary launched Lipola 
M (simvastatin ODT), a line extension of its 
block-buster, Zocor®, a cholesterol-lowering 
drug, in response to seventeen generic 
registrations of simvastatin applied for in 
Japan in 200424. 
 
Marketers build a better brand and company 
image when they offer a unique easier-to-take 
form that satisfies the need of an underserved 
patient population. 
 






As most drugs are unpalatable, orally 
disintegrating drug delivery systems usually 
contain the medicament in a taste-masked 
form. Delivery systems disintegrate or 
dissolve in patient’s oral cavity, thus releasing 
the active ingredients which come in contact 
with the taste buds; hence, taste-masking of 






In order to allow ODTs to disintegrate in the 
oral cavity, they are made of either very 
porous and soft-molded matrices or 
compressed into tablets with very low 
compression force, which makes the tablets 
friable and/or brittle, difficult to handle, and 
often requiring specialized peel-off blister 
packing that may add to the cost. Only few 
technologies can produce tablets that are 
sufficiently hard and durable to allow them to 
be packaged in multidose bottles, such as 
Wowtab® by Yamanouchi-Shaklee, and 






Several orally disintegrating dosage forms are 
hygroscopic and cannot maintain physical 
integrity under normal conditions of 
temperature and humidity. Hence, they need 
protection from humidity which calls for 





The application of technologies used for ODTs 
is limited by the amount of drug that can be 
incorporated into each unit dose. For 
lyophilized dosage forms, the drug dose must 
be lower than 400 mg for insoluble drugs and 
less than 60 mg for soluble drugs. This 
parameter is particularly challenging when 
formulating a fast-dissolving oral films or 
wafers. 
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Water-soluble drugs pose various formulation 
challenges because they form eutectic 
mixtures, which result in freezing-point 
depression and the formation of a glassy solid 
that may collapse upon drying because of loss 
of supporting structure during the sublimation 
process. Such collapse sometimes can be 
prevented by using various matrix-forming 
excipients such as mannitol than can induce 






The degree of ease when taking a tablet 
depends on its size. It has been reported that 
the easiest size of tablet to swallow is 7-8 mm 
while the easiest size to handle was one 
larger than 8 mm. Therefore, the tablet size 
that is both easy to take and easy to handle is 
difficult to achieve.  
 
Selection of ODT Drug Candidates 
 
Several factors must be considered when 
selecting drug candidates for delivery as ODT 
dosage forms. In general, an ODT is 
formulated as a bioequivalent line extension of 
an existing oral dosage form. Under this 
circumstance, it is assumed that the 
absorption of a drug molecule from the ODT 
occurs in the postgastric GIT segments, 
similar to the conventional oral dosage form. 
But this scenario may not always be the case. 
An ODT may have varying degrees of 
pregastric absorption and thus, the 
pharmacokinetic profiles will vary.29 Therefore, 
the ODT will not be bioequivalent to the 
conventional oral dosage form. For example, 
ODT formulations of selegiline, apomorphine, 
and buspirone have significantly different 
pharmacokinetic profiles compared with the 
same dose administered in a conventional 
dosage form31,32. 
 
It is possible that these differences may, in 
part, be attributed to the drug molecule, 
formulation, or a combination of both. If 
significantly higher plasma levels have been 
observed, pregastric absorption leading to the 
avoidance of first-pass metabolism may play 
an important role. This situation may have 
implications for drug safety and efficacy, 
which may need to be addressed and 
assessed in a marketing application for an 
ODT33.  For example, safety profiles may be 
improved for drugs that produce a significant 
amount of toxic metabolites mediated by first-
pass liver metabolism and gastric metabolism 
and for drugs that have a substantial fraction 
of absorption in the oral cavity and segments 
of the pregastric GIT. 
 
Drugs having ability to diffuse and partition 
into the epithelium of the upper GIT (log P > 1, 
or preferable > 2); and those able to permeate 
oral mucosal tissue are considered ideal for 
ODT formulations. Patients who concurrently 
take anticholinergic medications may not be 
the best candidates for these drugs. Similarly, 
patients with Sjögren’s syndrome or dryness 
of the mouth due to decreased saliva 
production may not be good candidates for 
these tablet formulations20.  Drugs with a short 
half-life and frequent dosing, drugs which are 
very bitter or otherwise unacceptable taste 
because taste masking cannot be achieved or 
those which require controlled or sustained 
release are unsuitable candidates of rapidly 
dissolving oral dosage forms. 
 
Researchers have formulated ODT for various 
categories of drugs used for therapy in which 
rapid peak plasma concentration is required to 
achieve the desired pharmacological 
response. These include neuroleptics, 
cardiovascular agents, analgesics, anti-
allergic, anti-epileptics, anxiolytics, sedatives, 
hypnotics, diuretics, anti-parkinsonism agents, 
anti-bacterial agents and drugs used for 
erectile dysfunction34. 
 
Approaches to ODT Development 
 
The fast disintegrating property of the tablet is 
attributable to a quick ingress of water into the 
tablet matrix resulting in its rapid 
disintegration. Hence, the basic approaches to 
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develop rapidly dissolving oral dosage forms 
include maximizing the porous structure of the 
tablet matrix, incorporating the appropriate 
disintegrating agent and using highly water-
soluble excipients in the formulation35. As is 
often the case, a technology that is originally 
developed to address a particular 
administration need can quickly become 
adopted as part of a pharmaceutical 
company’s product life cycle management 
strategy, which is precisely what has 
happened with ODT technologies. Several 
patented technologies with their basis of 
formulation are listed in Table 1. 
 
The technologies that have been used by 
various researchers to prepare orally 
disintegrating dosage forms include: Freeze-
Drying or Lyophilization, Molding, Direct 
Compression, Disintegrant addition, 
Sublimation, Spray Drying, Mass Extrusion, 
Cotton-candy process, NanoCrystalTM 
Technology, Oral films/wafers. Specific 
properties of the various ODT technologies 
are listed in Table 2. 
 
Broadening the scope of ODT technologies 
 
Industry observers point to broadening uses of 
ODT technology. These include the 
incorporation of macromolecules using ODT 
into vaccines. The success for other peptide 
and protein products will depend on 
bioavailability requirements and the 
application of methods to overcome oral 
absorption barriers. Other areas include: the 
incorporation of encapsulated APIs to achieve 
modified-release profiles within the 
convenience of an ODT; and the further 
development of superdisintegrants for 
incorporation into conventional, compressed 
tablets, potentially widening the opportunity for 
ODT development to non-specialist 
companies. 
 
Another emerging area is the wider 
application of ‘oral thin-strip technologies’. The 
use of thin-film strips is of growing interest in 
the pharmaceutical sector following the 
success of Listerine PocketPaks® in the 
United States. Thin-film strip technology uses 
a range of water-soluble polymers and is 
reported to be able to incorporate water-
soluble, insoluble, or taste-masked 
ingredients. The film is manufactured as a 
continuous sheet and then cut into individual 
doses prior to packing. The major limitations 
to this technology are the relatively low doses 
that can be accommodated (approximately 30 
mg) and its moisture sensitivity thus requiring 
specific unit-dose packaging to protect the 
product and ensure shelf life. Thin-film 
technology has primarily been used in over-
the-counter (OTC) products36 (see Table 3). 
Companies with oral thin-film technologies 
     
        Table 1: Some ODT patents 
 
Technology Basis Patent owner 
Zydis Lyophilization R.P.Scherer Inc. 
Quicksolv Lyophilization Janseen Pharmaceutica 






Compressed Tablets Cima Labs Inc. 
RapiTab Compressed Tablets Schwarz Pharma 




Fast melt Molding Élan Corp. 
Ziplets Molding Eurand 
FlashDose Cotton-candy process Fuisz Technology Ltd. 
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  Table 2: Advantage and disadvantages of patented technologies 
 
Technique Novelty Advantage(s) Disadvantage(s) 






Expensive process, poor 
stability at higher 
temperatures and 
humidities 
Orasolv Unique taste-masking, 
lightly compressed 
Taste-masking is two-
fold, quick dissolution 
Low mechanical strength 
Durasolv Compressed dosage 
form, Proprietary taste 
masking. 
Higher mechanical 
strength than Orasolv, 
good rigidity 
Inappropriate with larger 
doses. 
Flash Dose Unique spinning 
mechanism to produce a 
floss-like crystalline 
structure, much like 
cotton candy. 
High surface area for 
dissolution. 
High temperature required 
to melt the matrix can limit 
he use of heat-sensitive 
drugs, sensitive to moisture 
and humidity. 
Flashtab Compressed dosage form 
containing drug as 
microcrystals. 
Only conventional 








gives superior mouth feel. 
Adequate dissolution 
rate and hardness. 
No significant change in 
bioavailability. 
Oraquick Uses patented taste-
masking technology. 






Ziplet Incorporation of water-
insoluble inorganic 







properties can be 
obtained at high dose 
(450 mg) and high 
weight (850 mg) 
As soluble component 
dissolves, rate of water 
diffusion in to tablet is 
decreased because of 
formation of viscous 
concentrated solution. 
         
 
Table 3: Some oral thin-film pharmaceuticals and nutraceuticals 
Manufacturer Product Drug or supplement 
Novartis Theraflu Thin Strips Long Acting Cough Dextromethorphan 
Novartis Theraflu Thin Strips Multi-Symptom Diphenhydramine 
Novartis ThaminicThin Strips Long Acting Cough Dextromethorphan 
Novartis Triaminic Thin Strips Cough & Runny Nose Diphenhydramine 
Novartis Gas-X Thin Strip Anti Gas Simethicone 
Prestige Brands Little Colds Sore Throat Strips Pectin (from vitamin C) 
InnoZen Suppress Cough Strips Dextromethorphan 
InnoZen Suppress Herbal Cough Relief Strips Menthol 
Prestige Brands Chloraspetic Relief Strips Benzocaine; menthol 
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and products include LTS Lohmann Therapy 
Systems (West Caldwell, NI), Adhesives 
Research (Glen Rock, PA), Applied Pharma 
Research (Balerna, Switzerland), and Meldex 
International (Cambridge, UK)37. 
 
Elan’s proprietary NanoCrystal technology 
(NanomeltTM)38 can enable formulation as well 
as improve compound activity and final 
product characteristics. Decreasing particle 
size increases the surface area, which leads 
to an increase in dissolution rate. This can be 
accomplished predictably and efficiently using 
NanoCrystal technology. NanoCrystal 
particles are small particles of drug substance, 
typically less than 1000 nm in diameter, which 
are produced by milling the drug substance 
using a proprietary wet milling technique. This 
technology provides for pharmacokinetic 
benefits of orally administered nanoparticles 
(less than 2 microns) in the form of a rapidly 
disintegrating tablet matrix and wide range of 
doses (up to 200mg of API per unit). 
 
NanoCrystal colloidal dispersions of drug 
substance are combined with water-soluble 
GRAS (generally regarded as safe) 
ingredients, filled into blisters, and lyophilized. 
The resultant wafers are remarkably robust, 
yet dissolve in very small quantities of water in 
seconds. This approach is especially 
attractive when working with highly potent or 
hazardous materials because it avoids 
manufacturing operations (granulation, 
blending, and tableting) that generate large 
quantities of aerosolized powder and present 
much higher risk of exposure.  
 
ODT Evaluation of Special Concern 
 
Crushing strength and friability can be 
assessed as stated in pharmacopoeias. But 
some tests are of special concern and these 




Wetting time of dosage form is related to the 
contact angle. It needs to be assessed to give 
an insight into the disintegration properties of 
the tablets; a lower wetting time implies a 
quicker disintegration of the tablet.  For this 
purpose, a tablet is placed on a piece of tissue 
paper folded twice and kept in a small Petri 
dish (ID = 6.5 cm) containing 6 ml of water, 





The time for disintegration of ODTs is 
generally less than one minute and actual 
disintegration time that patient can experience 
ranges from 5-30 seconds. The standard 
procedure of performing disintegration test for 
these dosage forms has several limitations 
and they are not suitable for the measurement 
of very short disintegration times. The method 
needs to be modified for ODTs as 
disintegration is required without water; thus 
the test should mimic disintegration in salivary 
contents. A modified dissolution apparatus is 
applied to an ODT with a disintegration time 
that is too fast to distinguish differences 
between tablets when the compendial method 
is used. A basket sinker containing the tablets 
is placed just below the water surface in a 
container with 900 mL of water at 37 0C, and a 
paddle rotating at 100 rpm is used. The 
disintegration time is determined when the 
tablet has completely disintegrated and 
passed through the screen of the sinker40. 
Various scientists41 have developed new in 
vitro methods that allow an accurate 
determination of disintegration test. The 
disintegration test is performed using a texture 
analyzer instrument. In this test, a flat-ended 
cylindrical probe penetrates into the 
disintegrating tablet immersed in water. As the 
tablet disintegrates, the instrument is set to 
maintain a small force for a determined period 
of time. The plots of some distance traveled 
by the probe generated with the instrument’s 
software provide disintegration profile of the 
tablets as a function of time. The plot 
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facilitates calculation of the start and end-point 





The development of dissolution methods for 
ODTs is comparable to the approach taken for 
conventional tablets, and is practically 
identical. Dissolution conditions for drugs 
listed in a pharmacopoeia monograph, is a 
good place to start with scouting runs for a 
bioequivalent ODT. Other media such as 0.1 
M HCl and buffer (pH 4.5 and 6.8) should be 
evaluated for ODT much in the same way as 
their ordinary tablet counterparts.  
It has been suggested that USP 2 paddle 
apparatus is the most suitable and common 
choice for orally disintegrating tablets, with a 
paddle speed of 50 rpm commonly used.  
 
Moisture uptake studies 
43 
 
Moisture uptake studies for ODT should be 
conducted to have an insight into the stability 
of the formulation, as several excipients used 
are hygroscopic. Ten tablets from each 
formulation are kept in a desiccator over 
calcium chloride at 370C for 24 h. The tablets 
are then weighed and exposed to 75% RH at 
room temperature for two weeks. The required 
humidity (75% RH) is achieved by keeping 
saturated sodium chloride solution at the 
bottom of the desiccator for three days. One 
tablet as control (without superdisintegrant) is 
kept to assess the moisture uptake due to 
other excipients. Tablets are weighed and the 




In vivo studies have been performed on oral 
fast-disintegrating dosage forms to investigate 
their behavior in the oral–esophageal tract, 
their pharmacokinetic and therapeutic 
efficacy, and acceptability. Zydis’s residence 
time in the mouth and stomach, and its transit 
through the esophageal tract, was 
investigated using gamma-scintigraphy. Its 
dissolution and buccal clearance was rapid44; 
the esophageal transit time and stomach 
emptying time were comparable with those of 
traditional tablets, capsules, or liquid forms. A 
decreased intersubject variability in transit 
time was also observed45,46. Zydis also 
showed good therapeutic efficacy and patient 
acceptability - particularly in children47,48 or 
when easy administration and rapid onset of 
action were required (such as for patients 
undergoing surgery)49,50. The fast-
disintegrating forms examined showed 
improved pharmacokinetic characteristics 
when compared with reference oral solid 
formulations. For example, the absorption rate 
of the acetaminophen Flashtab was higher 
than that of the brand leader, while having the 
same bioavailability51. Increased bioavailability 
and improved patient compliance were 
observed in Lyoc formulations for different 
drugs such as phloroglucinol52, glafenine52, 
spironolactone53, and propyphenazone54. 
Using Zydis, all the drugs that can be 
absorbed through the buccal and esophageal 
mucosa exhibited increased bioavailability and 
side-effect reduction. This is helpful 
particularly in actives with marked first-pass 
hepatic metabolism44. Finally, the suitability of 
ODTs for long-term therapy was also 
assessed. Lyoc formulations containing 
aluminum were positively tested in patients 
with gastrointestinal symptoms55. 
 
Counseling points for ODTs
20 
 
Pharmacists are in the ideal position to 
become familiar with the various technologies, 
and educate their patients on what to expect 
upon taking their first dose. The majority of 
patients receiving ODT formulations have little 
understanding of this new dosage form. 
Patients may be surprised when tablets begin 
to dissolve in the oral cavity. They might 
expect a faster onset of therapeutic action. 
Clarification from the pharmacist can avoid 
any confusion or misunderstanding. Although 
no water is needed to allow the drug to 
disperse quickly and efficiently, most 
technologies utilize the body’s own salivation. 
Decreased volume of saliva may slow the rate 
of disintegration/dissolution and decrease the 
bioavailability of the product.  
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Although chewable tablets have been in the 
market for some time, they are not the same 
as the new ODTs. Patients for whom chewing 
is difficult or painful can use these new tablets 
easily. ODTs can be used easily in children 
who have lost their primary teeth, but do not 
have full use of their permanent teeth. 
Patients may mistake ODTs for effervescent 
tablets. Pharmacists may wish to stress the 
difference between the use of ODTs and 
effervescent tablets.  
 
ODT formulations are more susceptible to 
degradation via temperature and humidity. 
Some of the newest ODT formulations are 
dispensed in a conventional stock bottle. 
Pharmacists are advised to take care when 
dispensing such formulations to ensure they 
are not exposed to high levels of moisture or 
humidity. As with most drugs, patients should 
be advised to avoid storing ODTs in the 
medicine cabinet in the bathroom. 
 
Pharmacists have been alerted to exercise 
additional care when dispensing new 
prescriptions for ODT formulations. Most such 
products are available in the same strengths 
as traditional dosage forms. Prescribing 
physicians must make an additional notation 
for the dispensing of an ODT. A physician 
may also mistakenly believe the drug brand 
name is Zydis, for example, without identifying 
a specific drug. Verification with the 
prescribing practitioner may be necessary in 




Industrial applications include the following: 
 
• To develop an orally disintegrating 
dosage forms and to work with existing 
disintegrants 
• To further improvise upon the existing 
technology of ODTs 
• To optimize the blend of disintegrants or 
excipients to achieve ODTs 
• To select and develop proper packaging 
material and system for enhanced 
stability of the product and also develop 
a cost-effective product 
• To arrive at various taste-masking 
agents and prepare palatable dosage 
forms thereby increasing patient 
compliance 
• To develop disintegrants from different 
polymers which are used as coating 
materials by certain modifications and 




These dosage forms may be suitable for the 
oral delivery of drugs such as protein and 
peptide-based therapeutics that have limited 
bioavailability when administered by 
conventional tablets. These products usually 
degrade rapidly in the stomach. Should next 
generation drugs be predominantly protein or 
peptide based, tablets may no longer be the 
dominant format for dosing such moieties. 
Injections generally are not favored for use by      
patients unless facilitated by sophisticated 
auto-injectors. Inhalation is one good 
alternative system to deliver these drugs, but 
the increased research into biopharma-
ceuticals so far has generated predominantly 
chemical entities with low molecular weights. 
The developments of enhanced oral protein 
delivery technology by ODTs which may 
release these drugs in the oral cavity are very 
promising for the delivery of high molecular 




Orally disintegrating tablets have better 
patient acceptance and compliance and may 
offer improved biopharmaceutical properties, 
improved efficacy, and better safety compared 
with conventional oral dosage forms. 
Prescription ODT products initially were 
developed to overcome the difficulty in 
swallowing conventional tablets among 
pediatric, geriatric, and psychiatric patients 
with dysphagia. Today, ODTs are more widely 
available as OTC products for the treatment of 
allergies, cold, and flu symptoms. The target 
population has expanded to those who want 
Hirani et al   
Trop J Pharm Res, April 2009; 8 (2): 171 
convenient dosing anywhere, anytime, without 
water. The potential for such dosage forms is 
promising because of the availability of new 
technologies combined with strong market 
acceptance and patient demand. By paying 
close attention to advances in technologies, 
pharmaceutical companies can take 
advantage of ODTs for product line 
extensions or for first-to-market products. With 
continued development of new 
pharmaceutical excipients, one can expect the 
emergence of more novel technologies for 
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